- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-8726
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Chromogranin A: a useful biomarker in castration-resistant prostate cancer ; volume:41 ; number:2 ; day:17 ; month:12 ; year:2022 ; pages:361-369 ; date:2.2023
World journal of urology ; 41, Heft 2 (17.12.2022), 361-369, 2.2023
- Classification
-
Medizin, Gesundheit
- Creator
-
Ploussard, Guillaume
Rozet, François
Roubaud, Guilhem
Stanbury, Trevor
Sargos, Paul
Roupret, Morgan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00345-022-04248-0
- URN
-
urn:nbn:de:101:1-2023042821164295269037
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.01.2024, 8:04 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ploussard, Guillaume
- Rozet, François
- Roubaud, Guilhem
- Stanbury, Trevor
- Sargos, Paul
- Roupret, Morgan
- SpringerLink (Online service)
Other Objects (12)
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Ailanthone: a new potential drug for castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Ailanthone: a new potential drug for castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Targeting molecular resistance in castration-resistant prostate cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Longitudinal change in castration-resistant prostate cancer biomarker AST/ALT ratio reflects tumor progression
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Ailanthone: a new potential drug for castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer